Growth Factor-Antagonized Rexinoid Apoptosis Involves Permissive PPARγ/RXR Heterodimers to Activate the Intrinsic Death Pathway by NO

Cancer Cell

Volumn 16, Issue 3, 2009, Pages 220-231

  Shankaranarayanan, Pattabhiraman ^a   Rossin, Aurélie ^a   Khanwalkar, Harshal ^a   Alvarez, Susana ^c   Alvarez, Rosana ^c   Jacobson, Annica ^a   Nebbioso, Angela ^b   de Lera, Angel R ^c   Altucci, Lucia ^b   Gronemeyer, Hinrich ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF VIGO   (Spain)

Author keywords

CELLCYCLE

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 [2 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL) 1,3 DIOXOLAN 2 YL]BENZOIC ACID; ALITRETINOIN; BETA GALACTOSIDASE; BEXAROTENE; BMS 749; CASPASE 10; CASPASE 3; CASPASE 8; CASPASE 9; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS ASSOCIATED DEATH DOMAIN PROTEIN; GROWTH FACTOR; HETERODIMER; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 3; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P53; REACTIVE OXYGEN METABOLITE; RETINOID; RETINOID X RECEPTOR ALPHA; RETINOID X RECEPTOR BETA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INACTIVATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; BUTADIENES; CELL LINE, TUMOR; DIMERIZATION; ENZYME INHIBITORS; FEMALE; GENETIC VECTORS; HCT116 CELLS; HT29 CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LENTIVIRUS; MICE; MICE, NUDE; MUTAGENESIS, SITE-DIRECTED; NITRIC OXIDE; NITRILES; PLASMIDS; PPAR GAMMA; RANDOM ALLOCATION; RETINOID X RECEPTORS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 69249227485     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2009.07.029     Document Type: Article

References (54)

1. Adachi S., Okuno M., Matsushima-Nishiwaki R., Takano Y., Kojima S., Friedman S.L., Moriwaki H., and Okano Y. Phosphorylation of retinoid X receptor suppresses its ubiquitination in human hepatocellular carcinoma. Hepatology 35 (2002) 332-340
2. Adams M., Reginato M.J., Shao D., Lazar M.A., and Chatterjee V.K. Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen- activated protein kinase site. J. Biol. Chem. 272 (1997) 5128-5132
3. Altucci L., and Gronemeyer H. The promise of retinoids to fight against cancer. Nat. Rev. Cancer 1 (2001) 181-193
4. Altucci L., Leibowitz M.D., Ogilvie K.M., de Lera A.R., and Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat. Rev. Drug Discov. 6 (2007) 793-810
5. Altucci L., Rossin A., Hirsch O., Nebbioso A., Vitoux D., Wilhelm D., Guidez F., De Simone M., Schiavone E.M., Grimwade D., et al. Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor. Cancer Res. 65 (2005) 8754-8765
6. Beltran B., Mathur A., Duchen M.R., Erusalimsky J.D., and Moncada S. The effect of nitric oxide on cell respiration: A key to understanding its role in cell survival or death. Proc. Natl. Acad. Sci. USA 97 (2000) 14602-14607
7. Benoit G., Altucci L., Flexor M., Ruchaud S., Lillehaug J., Raffelsberger W., Gronemeyer H., and Lanotte M. RAR-independent RXR signaling induces t(15;17) leukemia cell maturation. EMBO J. 18 (1999) 7011-7018
8. Benoit G.R., Flexor M., Besancon F., Altucci L., Rossin A., Hillion J., Balajthy Z., Legres L., Segal-Bendirdjian E., Gronemeyer H., and Lanotte M. Autonomous rexinoid death signaling is suppressed by converging signaling pathways in immature leukemia cells. Mol. Endocrinol. 15 (2001) 1154-1169
9. Blumenschein Jr. G.R., Khuri F.R., von Pawel J., Gatzemeier U., Miller Jr. W.H., Jotte R.M., Le Treut J., Sun S.L., Zhang J.K., Dziewanowska Z.E., and Negro-Vilar A. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. J. Clin. Oncol. 26 (2008) 1879-1885
10. Brune B. Nitric oxide: NO apoptosis or turning it ON?. Cell Death Differ. 10 (2003) 864-869
11. Chen L.L., Gansbacher B., Gilboa E., Taetle R., Oval J., Hibbs M.S., Huang C.K., Clawson M.L., Bilgrami S., Schlessinger J., et al. Retroviral gene transfer of epidermal growth factor receptor into HL60 cells results in a partial block of retinoic acid-induced granulocytic differentiation. Cell Growth Differ. 4 (1993) 769-776
12. Chitnis M.M., Yuen J.S., Protheroe A.S., Pollak M., and Macaulay V.M. The type 1 insulin-like growth factor receptor pathway. Clin. Cancer Res. 14 (2008) 6364-6370
13. Clemmons D.R. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat. Rev. Drug Discov. 6 (2007) 821-833
14. Connelly L., Madhani M., and Hobbs A.J. Resistance to endotoxic shock in endothelial nitric-oxide synthase (eNOS) knock-out mice: a pro-inflammatory role for eNOS-derived no in vivo. J. Biol. Chem. 280 (2005) 10040-10046
15. Datta S., Magge S.N., Madison L.D., and Jameson J.L. Thyroid hormone receptor mediates transcriptional activation and repression of different promoters in vitro. Mol. Endocrinol. 6 (1992) 815-825
16. de Lera A.R., Bourguet W., Altucci L., and Gronemeyer H. Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat. Rev. Drug Discov. 6 (2007) 811-820
17. de Urquiza A.M., Liu S., Sjoberg M., Zetterstrom R.H., Griffiths W., Sjovall J., and Perlmann T. Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 290 (2000) 2140-2144
18. Debatin K.M. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol. Immunother. 53 (2004) 153-159
19. Dimmeler S., Haendeler J., Nehls M., and Zeiher A.M. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. J. Exp. Med. 185 (1997) 601-607
20. Elrod H.A., and Sun S.Y. PPARgamma and apoptosis in cancer. PPAR Res. 2008 (2008) 704165
21. Germain P., Iyer J., Zechel C., and Gronemeyer H. Coregulator recruitment and the mechanism of retinoic acid receptor synergy. Nature 415 (2002) 187-192
22. Girnun G.D., Naseri E., Vafai S.B., Qu L., Szwaya J.D., Bronson R., Alberta J.A., and Spiegelman B.M. Synergy between PPARgamma ligands and platinum-based drugs in cancer. Cancer Cell 11 (2007) 395-406
23. Gottardis M.M., Bischoff E.D., Shirley M.A., Wagoner M.A., Lamph W.W., and Heyman R.A. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res. 56 (1996) 5566-5570
24. Green D.R., and Kroemer G. The pathophysiology of mitochondrial cell death. Science 305 (2004) 626-629
25. Hallak H., Moehren G., Tang J., Kaou M., Addas M., Hoek J.B., and Rubin R. Epidermal growth factor-induced activation of the insulin-like growth factor I receptor in rat hepatocytes. Hepatology 36 (2002) 1509-1518
26. Indra A.K., Castaneda E., Antal M.C., Jiang M., Messaddeq N., Meng X., Loehr C.V., Gariglio P., Kato S., Wahli W., et al. Malignant transformation of DMBA/TPA-induced papillomas and nevi in the skin of mice selectively lacking retinoid-X-receptor alpha in epidermal keratinocytes. J. Invest. Dermatol. 127 (2007) 1250-1260
27. Kurmasheva R.T., and Houghton P.J. IGF-I mediated survival pathways in normal and malignant cells. Biochim. Biophys. Acta 1766 (2006) 1-22
28. Li C.Q., and Wogan G.N. Nitric oxide as a modulator of apoptosis. Cancer Lett. 226 (2005) 1-15
29. Li Y., Zhang Y., Hill J., Shen Q., Kim H.T., Xu X., Hilsenbeck S.G., Bissonnette R.P., Lamph W.W., and Brown P.H. The rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin. Cancer Res. 13 (2007) 6224-6231
30. Liby K., Royce D.B., Risingsong R., Williams C.R., Wood M.D., Chandraratna R.A., and Sporn M.B. A new rexinoid, NRX194204, prevents carcinogenesis in both the lung and mammary gland. Clin. Cancer Res. 13 (2007) 6237-6243
31. Liby K.T., Yore M.M., and Sporn M.B. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat. Rev. Cancer 7 (2007) 357-369
32. Lippman S.M., Sudbo J., and Hong W.K. Oral cancer prevention and the evolution of molecular-targeted drug development. J. Clin. Oncol. 23 (2005) 346-356
33. Macoritto M., Nguyen-Yamamoto L., Huang D.C., Samuel S., Yang X.F., Wang T.T., White J.H., and Kremer R. Phosphorylation of the human retinoid X receptor alpha at serine 260 impairs coactivator(s) recruitment and induces hormone resistance to multiple ligands. J. Biol. Chem. 283 (2008) 4943-4956
34. Mascrez B., Mark M., Krezel W., Dupe V., LeMeur M., Ghyselinck N.B., and Chambon P. Differential contributions of AF-1 and AF-2 activities to the developmental functions of RXR alpha. Development 128 (2001) 2049-2062
35. Matsuzaki H., Tamatani M., Mitsuda N., Namikawa K., Kiyama H., Miyake S., and Tohyama M. Activation of Akt kinase inhibits apoptosis and changes in Bcl-2 and Bax expression induced by nitric oxide in primary hippocampal neurons. J. Neurochem. 73 (1999) 2037-2046
36. McAlpine C.A., Barak Y., Matise I., and Cormier R.T. Intestinal-specific PPARgamma deficiency enhances tumorigenesis in ApcMin/+ mice. Int. J. Cancer 119 (2006) 2339-2346
37. Minshall C., Arkins S., Straza J., Conners J., Dantzer R., Freund G.G., and Kelley K.W. IL-4 and insulin-like growth factor-I inhibit the decline in Bcl-2 and promote the survival of IL-3-deprived myeloid progenitors. J. Immunol. 159 (1997) 1225-1232
38. Moncada S., and Erusalimsky J.D. Does nitric oxide modulate mitochondrial energy generation and apoptosis?. Nat. Rev. Mol. Cell Biol. 3 (2002) 214-220
39. Ocadiz-Delgado R., Castaneda-Saucedo E., Indra A.K., Hernandez-Pando R., and Gariglio P. Impaired cervical homeostasis upon selective ablation of RXRalpha in epithelial cells. Genesis 46 (2008) 19-28
40. Orlandi A., Bianchi L., Costanzo A., Campione E., Giusto Spagnoli L., and Chimenti S. Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene. J. Invest. Dermatol. 122 (2004) 1037-1041
41. Ramlau R., Zatloukal P., Jassem J., Schwarzenberger P., Orlov S.V., Gottfried M., Pereira J.R., Temperley G., Negro-Vilar R., Rahal S., et al. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. J. Clin. Oncol. 26 (2008) 1886-1892
42. Rodriguez-Tarduchy G., Collins M.K., Garcia I., and Lopez-Rivas A. Insulin-like growth factor-I inhibits apoptosis in IL-3-dependent hemopoietic cells. J. Immunol. 149 (1992) 535-540
43. Saez E., Olson P., and Evans R.M. Genetic deficiency in Pparg does not alter development of experimental prostate cancer. Nat. Med. 9 (2003) 1265-1266
44. Schneiderhan N., Budde A., Zhang Y., and Brune B. Nitric oxide induces phosphorylation of p53 and impairs nuclear export. Oncogene 22 (2003) 2857-2868
45. Shulman A.I., Larson C., Mangelsdorf D.J., and Ranganathan R. Structural determinants of allosteric ligand activation in RXR heterodimers. Cell 116 (2004) 417-429
46. So P.L., Lee K., Hebert J., Walker P., Lu Y., Hwang J., Kopelovich L., Athar M., Bickers D., Aszterbaum M., and Epstein Jr. E.H. Topical tazarotene chemoprevention reduces basal cell carcinoma number and size in Ptch1+/- mice exposed to ultraviolet or ionizing radiation. Cancer Res. 64 (2004) 4385-4389
47. Solomin L., Johansson C.B., Zetterstrom R.H., Bissonnette R.P., Heyman R.A., Olson L., Lendahl U., Frisen J., and Perlmann T. Retinoid-X receptor signalling in the developing spinal cord. Nature 395 (1998) 398-402
48. Stegmaier K., Corsello S.M., Ross K.N., Wong J.S., Deangelo D.J., and Golub T.R. Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood 106 (2005) 2841-2848
49. Thomas L.R., Johnson R.L., Reed J.C., and Thorburn A. The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation. J. Biol. Chem. 279 (2004) 52479-52486
50. Wanebo H.J., Argiris A., Bergsland E., Agarwala S., and Rugo H. Targeting growth factors and angiogenesis; using small molecules in malignancy. Cancer Metastasis Rev. 25 (2006) 279-292
51. Wu G.S., Burns T.F., McDonald III E.R., Jiang W., Meng R., Krantz I.D., Kao G., Gan D.D., Zhou J.Y., Muschel R., et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 17 (1997) 141-143
52. Yamashita D., Yamaguchi T., Shimizu M., Nakata N., Hirose F., and Osumi T. The transactivating function of peroxisome proliferator-activated receptor gamma is negatively regulated by SUMO conjugation in the amino-terminal domain. Genes Cells 9 (2004) 1017-1029
53. Yamazaki K., Shimizu M., Okuno M., Matsushima-Nishiwaki R., Kanemura N., Araki H., Tsurumi H., Kojima S., Weinstein I.B., and Moriwaki H. Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells-phosphorylated RXR alpha is a critical target for colon cancer management. Gut 56 (2007) 1557-1563
54. Zeisig B.B., Kwok C., Zelent A., Shankaranarayanan P., Gronemeyer H., Dong S., and So C.W. Recruitment of RXR by homotetrameric RARalpha fusion proteins is essential for transformation. Cancer Cell 12 (2007) 36-51